New study aims to uncover how a Mucus-Targeting drug helps COPD patients
NCT ID NCT07329946
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 22 times
Summary
This study looks at how the drug erdosteine affects inflammation and oxidative stress in people with COPD. Researchers will compare 15 patients taking erdosteine plus standard care with 15 patients on standard care alone over 4 weeks. The goal is to understand the biological mechanisms behind erdosteine's clinical benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
L. Sacco Hospital
Milan, 20157, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.